OncoC4 Secures $50 Million in Series B Funding for Cancer Therapy Development

October 03, 2025
OncoC4, a biotechnology company, has closed a Series B financing round of nearly $50 million to advance its pipeline of cancer therapies, announced in a press release.

OncoC4 has closed a Series B financing round of nearly $50 million, announced in a press release. The round was led by GBA Fund, with participation from the company's co-founders and existing investors, including HM Capital, 3E Bioventures Capital, and Kaitai Capital.

Founded in 2020 by immunologists Dr. Yang Liu and Dr. Pan Zheng, OncoC4 is focused on developing innovative therapies for cancer and neurodegenerative diseases. The funds from this financing round will be used to advance the clinical development of the company's pipeline programs, which target both novel and well-validated targets across oncology and immunological diseases.

Dr. Yang Liu, Co-Founder and CEO of OncoC4, expressed gratitude for the investors' support and emphasized the company's commitment to advancing its core pipeline and expanding business development activities globally.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

AI Funding News Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Funding

10/03
Aisthesis Medical Secures $1.2M for AI Sepsis Prediction Platform
10/03
Clarifeye Secures €4M to Scale AI Agents from Expert Knowledge
10/03
Alpine Intel Acquires HMI to Expand Insurance Solutions
10/02
Yasp Secures $5 Million to Advance AI Model Optimization
10/02
OpenAI Completes $6.6 Billion Share Sale at $500 Billion Valuation

More from: Life Sciences

10/03
Twin Health's AI Digital Twin Outperforms Traditional Diabetes Care
10/03
MedHub-AI's AutocathFFR Gains Reimbursement Approval in Japan
10/03
Aisthesis Medical Secures $1.2M for AI Sepsis Prediction Platform
10/03
ExQor Technologies Advances Brain Regenerative Medicine for Alzheimer's
10/03
AIxMed and Biopticka Collaborate on AI-Powered Cytology in Europe

Subscribe to AI Funding Brief

AI Token Webinar

Market report

AI’s Time-to-Market Quagmire: Why Enterprises Struggle to Scale AI Innovation

ModelOp

The 2025 AI Governance Benchmark Report by ModelOp provides insights from 100 senior AI and data leaders across various industries, highlighting the challenges enterprises face in scaling AI initiatives. The report emphasizes the importance of AI governance and automation in overcoming fragmented systems and inconsistent practices, showcasing how early adoption correlates with faster deployment and stronger ROI.

Read more

You May Also Like